Dr Dooshima Kwange Department of Veterinary and Pest Control Services FMARD

Similar documents
Dr. Gérard Moulin Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products BP FOUGERES CEDEX, FRANCE

OIE Conference on Veterinary Medicinal Products in the Middle East

The OIE Relevant Standards and Guidelines for Vaccines

Dr A T Sigobodhla. Regional Workshop for OIE National Focal Points for Veterinary Products (Cycle V): Ezulwini, Swaziland, 6-8 December 2017

The OIE Relevant Standards and Guidelines for Veterinary Medicinal Products

Contents & results of 3 years of VMP FP training Susanne Münstermann OIE Scientific and Technical Department

International Harmonisation in the Field of Pharmacovigilance from an OIE perspective

All medicinal products (for human and veterinary use) are regulated under the single Pharmaceutical Act.

VICH:Organization,Guidelines and Global Outreach

OIE Collaborating Centres Reports Activities

RECENT ACTIVITIES OF THE NATIONAL FOCAL POINT FOR VETERINARY PRODUCTS - SWAZILAND PRESENTATION TO

Dr. Gérard Moulin AFSSA/ANMV OIE Collaborating Centre on Veterinary medicinal products BP FOUGERES CEDEX, FRANCE

OIE Strategy on Antimicrobial Resistance and the Prudent Use of Antimicrobials in Animals Part I

Introduction SEAVDRAC. 23 October Prof G E Swan. Southern and Eastern African Veterinary Drug Regulatory Affairs conference

VICH :To a wider international harmonisation of registration requirements

Good clinical practice a tool to refine fish research - an assessors view

International approach for veterinary medicinal products: OIE and Codex alimentarius

Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health

STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: REPRODUCTION TESTING

The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial & Aquatic Animals

Results of the questionnaire on Veterinary Medicinal Products in the Middle East Damascus, Syria, 2-4 December 2009

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

OIE Strategy on Antimicrobial Resistance and the need for new diagnostic tools

OIE Standards for: Animal identification and traceability Antimicrobials

Overview of the OIE PVS Pathway

Legislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

OIE Activities for the Containment of Antimicrobial Resistance. Dr Elisabeth Erlacher-Vindel, Deputy Head of the Scientific and Technical Department

OIE GLOBAL DATABASE ON AMU IN ANIMALS

Antimicrobial resistance: the challenges for animal health

OIE Strategy for Veterinary Products and Terms of Reference for the OIE National Focal Points

OIE capacity-building activities

Support for OIE Member Countries OIE PVS / Gap Analysis, Reference Laboratories and twinning programmes

Prudent use of antimicrobial agents Dairy Sector Initiatives. Robin Condron Dairy Australia

VICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms

GOOD GOVERNANCE OF VETERINARY SERVICES AND THE OIE PVS PATHWAY

All participants at the Salt Lake City confirmed strong support for the OIE assuming an international laboratory animal welfare role.

VMP Focal point training Casablanca 6 8 December Dr Susanne Münstermann

Private Sector Perspectives IFAH (worldwide)

Illegal veterinary drugs. How to ensure the quality and traceability of Veterinary Medicinal Products

Quality of veterinary medicines

Recognition of Export Controls and Certification Systems for Animals and Animal Products. Guidance for Competent Authorities of Exporting Countries

Recommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee

OIE strategy on AMR and the Prudent Use of Antimicrobials

YOU YOU WE NEED. To implement the new Antimicrobial Resistance campaign TO HANDLE ANTIMICR BIALS WITH CARE. October Veterinary Services

Combat Antimicrobial Resistance

Approved by the Food Safety Commission on September 30, 2004

PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 13 to 15 July 2004

Action for Combatting AMR in Veterinary Sector

Outline of Risk Analysis for Veterinary Vaccines in Japan

VICH and the Registration of Veterinary Drugs

OVERVIEW OF EMERGING ANIMAL DISEASE PREPAREDNESS AND RESPONSE PLAN

OIE International standards related to control, inspection and approval procedures

Regulation to control Autogenous Vaccine in Thailand

OIE Quality Standard for Veterinary Laboratories

The OIE activities to protect animal and human health: Potential contributions in the fight against counterfeit drugs

Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP Adopted 2005

Mutual Recognition of Immunological Veterinary Products in East Africa. NOEL AINEPLAN National Drug Authority Uganda

OIE global strategy for rabies control, including regional vaccine banks

Terrestrial and Aquatic Manuals OIE Standard Setting Process

Science Based Standards In A Changing World Canberra, Australia November 12 14, 2014

Collection of quantitative data on the use of antimicrobial agents including the establishment of an OIE database

The impact of Good Veterinary Services Governance (GVSG) on the control over Veterinary Medicinal Products (VMP s)

The OIE-PVS: a tool for good Governance of Veterinary Services

Antimicrobial resistance. Summary of OIE Activities

Antimicrobial Resistance Direction Statement for Animals and Plants, and Work Programme

OIE standards on the use of antimicrobials and antimicrobial resistance monitoring

Antimicrobial use and Antimicrobial resistance: chapter 6.7 and 6.8 of the OIE Terrestrial Animal Health

Bovine Brucellosis Control of indirect ELISA kits

USA ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

14th Conference of the OIE Regional Commission for Africa. Arusha (Tanzania), January 2001

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE

international news RECOMMENDATIONS

Rabies Communication in practice, investments and regional outlook. Chika Nwosuh National Veterinary Research Institute, Vom, Nigeria

EXPERIENCE ON ANTIMICROBIAL USE AND RESISTANCE IN KENYA

Office International des Épizooties World Organisation for Animal Health created in 1924 in Paris

( ) Page: 1/8 COMMUNICATION FROM THE WORLD ORGANISATION FOR ANIMAL HEALTH (OIE)

OIE AMR Strategy, One Health concept and Tripartite activities

Collection of quantitative data on the use of antimicrobial agents including the establishment of an OIE database

Position Statement. Responsible Use of Antibiotics in the Australian Chicken Meat Industry. 22 February What s the Issue?

FAO-OIE-WHO Tripartite Positions and Actions on Antimicrobial Resistance (AMR)

The Role of OIE Reference Laboratories and Collaborating Centres in Disease Reporting

OIE International Solidarity: General Overview

Illegal veterinary medicines

MEDICINES CONTROL AUTHORITY OF ZIMBABWE. Country experience in prudent and responsible use of antimicrobials

Terrestrial and Aquatic Manuals and mechanism of standard adoption

Terrestrial and Aquatic Manuals and the mechanism of standard adoption

Building Competence and Confidence. The OIE PVS Pathway

World Organisation for Animal Health

Recommendation for the basic surveillance of Eudravigilance Veterinary data

OIE activities related to wildlife and biodiversity

2017 EU Action Plan against AMR state of play of implementation One-Health Network on AMR 26 October Brussels

General Directorate of Animal Health and EpizooticDiseases Control. Dr.Sabah Hassan Abdelgadir Sudan Focal Point for Veterinary products

WHO perspective on antimicrobial resistance

OIE activities on rabies: PVS, vaccine banks and the OIE twinning

FUNDAMENTAL PRINCIPLES OF THE QUALITY OF VETERINARY SERVICES

China Training Seminar on the OIE PVS Tool for East Asia Seoul, Republic of Korea, April 2016

Role and responsibilities of the veterinarian in the aquatic sector The OIE perspective

OIE stray dog control standards and perspective. Dr. Stanislav Ralchev

Transcription:

Dr Dooshima Kwange Department of Veterinary and Pest Control Services FMARD Presented at the Regional Seminar for OIE Focal Points for Veterinary Products (Cycle V), Ezulwini, Swaziland. 6-8 December 2017

Introduction Applicable Guidelines Nigeria Situation Challenges Way Forward

VICH International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products Members EU, Japan and USA. Australia, Canada, New Zealand and South Africa have observer status

It establishes and implements harmonized technical requirements (guidelines) for the registration of veterinary medicinal products in the VICH regions, This ensures high quality, safety and efficacy standards and Minimizes the use of test animals and costs of product development

Veterinary Products are important tools in the prevention and control of animal diseases. These include vaccines, veterinary medicines, such as antimicrobial agents, and diagnostic kits.

The Regulatory Authority (RA) assesses data of studies carried out on the VMP during development and production from the manufacturer to ensure it is safe and efficacious for use in animals The product when it has passed the test is registered for marketing. The RA still carries out post marketing survey to track the distribution and use of the VMP

56 guidelines for Industry and Regulatory Authorities 6 guidelines have been revised 2 guidelines are under revision Focus is on pharmaceuticals, biologicals, pharmacovigilance and general aspects

The VICH guidelines are used by industry and regulatory bodies for technical requirements in registration of veterinary products Guidelines are administrative tools that do not have the force of law Alternative approaches to the principles and practices described in the guidelines may be acceptable but must be supported by adequate scientific justification.

In the Nigeria context the focus for implementation of the VICH guidelines will be on the National Agency for Food and Drug Administration and Control (NAFDAC) and the National Veterinary Research Institute (NVRI) NAFDAC gives marketing authorization, conducts post-market surveys and carries out parmacovigilance. The Directorate of Veterinary Medicines and Allied Products (VMAP) has been newly established NVRI produces veterinary vaccines and other biologicals

Regulatory Authority GL24 Pharmacovigilance of veterinary medicinal products: Management of Adverse Event Reports (AERs) GL27 Guidance on pre-approval information for registration of new veterinary medicinal products for food producing animals with respect to antimicrobial resistance GL29 Pharmacovigilance of veterinary medicinal products: Management of periodic summary update reports GL30 Pharmacovigilance of veterinary medicinal products: Controlled list of terms

Industry GL9 Good clinical practice, this is to provide guidance on the design and conduct of clinical studies of veterinary products in the target species. GL17 Stability testing of new biotechnological/biological products GL25 testing for residual formaldehyde in inactivated veterinary vaccines GL26 testing for residual moisture in freeze dried veterinary vaccines

GL34 Testing for detection of Mycoplasma contamination GL41 Target animal (TA) safety: Examination of live veterinary vaccine in TA for absence of reversion to virulence GL44 Target animal safety for veterinary live and inactivated vaccines GL50 Criteria to waive target animal batch safety testing for veterinary vaccines

NVRI GL9 For Good Clinical Practice the Institute produces all its veterinary vaccines and other biologicals in accordance to the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals by the World Organisation for Animal Health (OIE). http://www.oie.int/manualof-diagnostic-tests-and-vaccines-forterrestrial-animals/

GL17 Stability testing of new biotechnological/biological products is not carried out in the Institute due to the unavailability of the relevant equipment and associated materials GL25/26 testing for residual formaldehyde in inactivated veterinary vaccine and residual moisture in freeze dried veterinary vaccines is not done in the Institute due to the unavailability of the relevant equipment and associated materials

GL34 Testing for detection of Mycoplasma contamination is done using the relevant primers in collaboration with the Molecular Biology of the Institute. NB: batches of vaccines produced are tested at PANVAC for quality control purposes

GL41/44 Target animal (TA) safety: Examination of live veterinary vaccine in TA for absence of reversion to virulence and Target animal safety for veterinary live and inactivated vaccines are not done due to the unavailability of an animal experimental house and the required specific pathogen free experimental animal species required for the procedure

GL50 Criteria to waive target animal batch safety testing for veterinary vaccines is done based on the OIE guidelines for vaccine production in consonance with Good Laboratory Practice as governed by the ISO 17025 Standards for Testing and calibrating laboratories. The Institute is presently implementing a Quality Management system (QMS) in accordance with the ISO 9001 in general and specifically working towards an ISO 17025 accreditation for the production of veterinary vaccines.

NAFDAC Not using the VICH guidelines Agency has developed guidelines for monitoring the adverse event of veterinary medicinal products that the Agency has established an information data bank on adverse events for human drugs (yet to be done for VMP)

Lack of clear knowledge and understanding of VICH guidelines and activities by Regulatory Authority and Industry Weak capacity of regulatory body (VMAPD) to apply VICH guidelines or other requirements Infrastructure deficit within industry for implementation of VICH guidelines or other requirements

Greater awareness drive for stakeholders especially industry and regulatory authorities VICH to explore means to assist NAFDAC and NVRI find funding for implementation of VICH guidelines Advocacy to Regional Economic Communities (RECs) should be made

National Agency for Food and Drug Administration and Control (NAFDAC) National Veterinary Research Institute (NVRI) Federal Ministry of Agriculture and Rural Development World Organization for Animal Health (OIE)